Disclosed are a glycerol derivative that is useful for improving, preventing or treating inflammation-related diseases by inhibiting overexpression of various inflammatory cytokines such as IL-4, IL-6 and so on, or chemokine CXCL8 and reducing migration of HL-60 cell lines, preparation method therefor, and an immunomodulator containing the same as active ingredient. It includes a glycerol derivative represented by Chemical formula 2 or 3 in the specification.

The present disclosure provides certain N-Acylethanolamide derivatives, and uses relating thereto.

The present disclosure provides certain N-Acylethanolamide derivatives, and uses relating thereto.

A genus of proteolysis-targeting chimeras (PROTACs)-type compounds/antiestrogens has now been found that act as selective estrogen receptor degraders (SERDs) and estrogen receptor antagonists by degrading and antagonizing ERa in breast cancer cells. The compounds are of the following genus: The compounds described herein exhibit anti-proliferative effects, and are potentially useful, alone or in combination with other therapies, for the treatment of breast cancer. In general, these compounds combine a tight binding ERa targeting ligand tethered to a recognition motif or degron. Once bound, the degron recruits destructive cellular components and the targeted receptor (i.e., ERa) is degraded (i.e., destroyed) or antagonized.

##STR00001##

A genus of proteolysis-targeting chimeras (PROTACs)-type compounds/antiestrogens has now been found that act as selective estrogen receptor degraders (SERDs) and estrogen receptor antagonists by degrading and antagonizing ERa in breast cancer cells. The compounds are of the following genus: The compounds described herein exhibit anti-proliferative effects, and are potentially useful, alone or in combination with other therapies, for the treatment of breast cancer. In general, these compounds combine a tight binding ERa targeting ligand tethered to a recognition motif or degron. Once bound, the degron recruits destructive cellular components and the targeted receptor (i.e., ERa) is degraded (i.e., destroyed) or antagonized.

##STR00001##

The present disclosure discloses a calcium-based catalyst and a method for catalytically synthesizing an alkanolamide surfactant thereof, and belongs to the technical field of surfactant synthesis. In the present disclosure, the compounded calcium-based catalyst is prepared, and the calcium-based catalyst is utilized to catalyze reaction of fat and oil or fatty acid ester and alkanol amine to synthesize the alkanolamide surfactant with light color and less free alkanol amine, which facilitates application in daily chemicals. The calcium-based catalyst in the present disclosure has a slow release feature, so that the catalyst still has relatively high catalytic reaction activity in the late reaction period, it is guaranteed that the alkanol amine is converted into the alkanolamide surfactant with a high conversion rate, the conversion rate of the alkanol amine is high, the residual quantity of the alkanol amine in the product is low, and the risk of nitrosamine caused by the residual alkanol amine in the product is greatly lowered. Meanwhile, the speed in the early reaction period is greatly reduced due to control of slow release of the catalyst, and a deepened color of the product caused by poor heat transfer in the synthesis process due to excessively fast reaction in the early period is effectively avoided.

The present disclosure discloses a calcium-based catalyst and a method for catalytically synthesizing an alkanolamide surfactant thereof, and belongs to the technical field of surfactant synthesis. In the present disclosure, the compounded calcium-based catalyst is prepared, and the calcium-based catalyst is utilized to catalyze reaction of fat and oil or fatty acid ester and alkanol amine to synthesize the alkanolamide surfactant with light color and less free alkanol amine, which facilitates application in daily chemicals. The calcium-based catalyst in the present disclosure has a slow release feature, so that the catalyst still has relatively high catalytic reaction activity in the late reaction period, it is guaranteed that the alkanol amine is converted into the alkanolamide surfactant with a high conversion rate, the conversion rate of the alkanol amine is high, the residual quantity of the alkanol amine in the product is low, and the risk of nitrosamine caused by the residual alkanol amine in the product is greatly lowered. Meanwhile, the speed in the early reaction period is greatly reduced due to control of slow release of the catalyst, and a deepened color of the product caused by poor heat transfer in the synthesis process due to excessively fast reaction in the early period is effectively avoided.

The present invention relates to a polymerizable polyacidic polymer and to a process for preparing the polymerizable polyacidic polymer. Furthermore, the present invention relates to an aqueous dental composition comprising the polymerizable polyacidic polymer, to a use of the polymerizable polyacidic polymer for the preparation of a dental composition and to an acrylic acid derivative copolymer.

The present invention relates to a polymerizable polyacidic polymer and to a process for preparing the polymerizable polyacidic polymer. Furthermore, the present invention relates to an aqueous dental composition comprising the polymerizable polyacidic polymer, to a use of the polymerizable polyacidic polymer for the preparation of a dental composition and to an acrylic acid derivative copolymer.

The present invention provides compositions and methods for relieving pain at a site in a human or animal in need thereof by administering at a discrete site in a human or animal in need thereof a dose of capsaicin in an amount effective to denervate a discrete site without eliciting an effect outside the discrete location, the dose of capsaicin ranging from 1 g to 3000 g.